Toward the Comprehensive Systematic Enumeration and Synthesis of Novel Kinase Inhibitors Based on a 4-Anilinoquinazoline Binding Mode
Authors:
- 9 February 2010
- journal article
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 50 (4) , 525-533
Abstract
There are currently eight small-molecule kinase inhibitors approved as cancer treatments, and a significantly larger number of compounds are in the earlier stages of clinical development. Although kinase inhibitors are most commonly developed in a cancer setting, other disease areas have been targeted. The vast majority of reported kinase small-molecule inhibitors contain functionalities that interact with the adenosine triphosphate (ATP) binding site of the kinase. The 4-anilinoquinazolines have previously been reported as potent epidermal growth factor receptor (EGFR) inhibitors, binding at the ‘hinge’ region of the ATP site. Subsequently, this chemical series has been optimized against a number of different kinases including Src and Aurora B. Here, we detail the computational enumeration of ring systems that have the ability to make comparable interactions to the 4-anilinoquinazoline core. These were prioritized by computational, medicinal, and synthetic chemistry input, and a number of libraries were subsequently synthesized.Keywords
This publication has 27 references indexed in Scilit:
- Synthesis of Quinazolines as Tyrosine Kinase InhibitorsAnti-Cancer Agents in Medicinal Chemistry, 2009
- Gefitinib for the treatment of non-small-cell lung cancerExpert Review of Anticancer Therapy, 2009
- Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian PerspectiveJapanese Journal of Clinical Oncology, 2008
- Erlotinib: the first biologic in the management of pancreatic cancerExpert Opinion on Pharmacotherapy, 2008
- Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatmentExpert Review of Respiratory Medicine, 2008
- Lapatinib in the treatment of breast cancerExpert Review of Anticancer Therapy, 2007
- LapatinibNature Reviews Drug Discovery, 2007
- Synthesis of 4-(Phenylamino)pyrimidine Derivatives as ATP-Competitive Protein Kinase Inhibitors with Potential for Cancer ChemotherapyCurrent Organic Chemistry, 2000
- Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolinesBreast Cancer Research and Treatment, 1996
- A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine KinaseScience, 1994